- Report
- November 2024
Global
From €7083EUR$7,500USD£6,024GBP
- Report
- November 2021
- 175 Pages
Global
From €4675EUR$4,950USD£3,976GBP
- Report
- June 2022
- 260 Pages
Global
From €3943EUR$4,175USD£3,354GBP
- Report
- June 2021
Global
From €7083EUR$7,500USD£6,024GBP
- Report
- October 2024
- 87 Pages
Global
From €3500EUR$3,970USD£3,081GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$3,970USD£3,081GBP
The Hepatitis B Test is a type of infectious disease test used to detect the presence of the hepatitis B virus (HBV) in a person's blood. It is used to diagnose acute and chronic HBV infections, as well as to monitor the effectiveness of treatment. The test is typically performed using a blood sample, which is then tested for the presence of HBV-specific antibodies or antigens. The test is also used to screen for HBV infection in high-risk populations, such as healthcare workers and those with multiple sexual partners.
The Hepatitis B Test market is a subset of the larger infectious disease testing market, which is estimated to be worth billions of dollars. The market is driven by the increasing prevalence of HBV infections, as well as the need for accurate and timely diagnosis and treatment.
Some companies in the Hepatitis B Test market include Abbott Laboratories, Bio-Rad Laboratories, DiaSorin, F. Hoffmann-La Roche, and Siemens Healthineers. Show Less Read more